On the occasion of Children's Week, Lek, a Sandoz company, organised a series of educational workshops with a laboratory at six schools in Koroška region
- During Children’s Week, in the Upper Meža Valley, supported by Lek, a Sandoz company, and in cooperation with the Association of Friends of Youth, creative workshops for children were held, with a mini laboratory, prepared by Lek associates.
- Lek, a Sandoz company, has been closely involved in the Prevalje local environment for nearly four decades. It supports associations and organizations which contribute to better quality of life of children, youth, and elderly.
The first week in October has been dedicated to children since 1954. In this year’s Children’s Week, organized by the Slovenian Association of Friends of Youth (SAFY) between 5 and 11 October, creative workshops for children are being held also in Koroška region, with a support of Lek, a Sandoz company. The associates from Lek, who are volunteers, are preparing on Wednesday and Thursday, 7 and 8 October, a mini-laboratory with interesting experiments for children at six primary schools in the region: at Prevalje, Mežica, Črna na Koroškem and Ravne na Koroškem.
Lek, a Sandoz company, has recognized the important role of the Slovenian Association of Friends of Youth already 17 years ago, and is supporting its activities ever since. In this regard, they have co-created over the past 17 years the Wink at the Sun initiative, which enables socially underprivileged children to experience careless holidays on the see or in the mountains. »For children, carefree holidays, packed with new knowledge and experience, making new friendships and holiday memories, is invaluable. They develop habits and values that can grow only in a supportive environment where the children and their needs come first. Every child should have this opportunity Therefore, Lek, a Sandoz company, has been enabling with maximum dedication free holidays for children for 17 years as part of the Wink of the Sun initiative. In this year 11 children from Koroška region have enjoyed holidays with the support of the Wink of the Sun initiative, together with 340 children from other parts of Slovenia,« said Katarina Klemenc, Head of Corporate Communication at Lek, a Sandoz company in the introduction to Children’s Week.
Prevalje site has been developing continuously and is an important part of Sandoz
Since the beginning of its operation in 1978, the Prevalje site of Lek, a Sandoz company, has been continuously developing. At Prevalje, one of the most important Sandoz products, a broad spectrum antibiotic, is manufactured, therefore the site is an important part of Novartis’ generic division Sandoz. The production capacities have been continuously growing and it is expected that later this year, the five billionth tablet of a broad spectrum antibiotic will be manufactured at Prevalje.
Lek, a Sandoz, company, maintains its role as a major employer in the region with currently more than 300 associates at Prevalje. Last year alone, the number of employees at the Prevalje site increased by 15%. Of these, more than 90% of the employees come from the local area where unemployment is an issue of great concern.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, a division of Novartis, is a global leader in generic pharmaceuticals, driving sustainable access to high-quality healthcare. Sandoz employs more than 26,000 people worldwide and supplies a broad range of affordable products to patients and customers around the globe.
The Sandoz global portfolio comprises approximately 1,100 molecules, which accounted for 2014 sales of USD 9.6 billion. Sandoz holds the global #1 position in biosimilars as well as in generic anti-infectives, ophthalmics and transplantation medicines. Sandoz also holds leading global positions in key therapeutic areas ranging from generic injectables, dermatology and respiratory to cardiovascular, metabolism, central nervous system, pain and gastrointestinal.
Sandoz develops, produces and markets finished dosage form (FDF) medicines as well as intermediary products including active pharmaceutical ingredients (APIs) and biotechnological substances. Nearly half of the Sandoz portfolio is in differentiated products – medicines that are scientifically more difficult to develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has consistently driven growth in selected geographies and differentiated product areas through a series of targeted acquisitions, including Hexal (Germany), EBEWE Pharma (Austria), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-counter products. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 130,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32